Nitazoxanide (178; Figure 39), a broad‐spectrum antiparasitic drug, was reported to inhibit SARS‐CoV‐2 (EC50, 2.12 μM in Vero E6 cells). 215  It is also an IFN‐inducing agent, and it is being studied for treating a wide range of infections.